To help support its commercialisation, Proteomics released the results of its latest PromarkerEndo trial, involving 704 blood plasma samples, to leading medical specialists and researchers at the prestigious World Congress on Endometriosis in Sydney in May.
The trial used a diagnostic test consolidated from earlier prototype models to compare cases of endometriosis with general population controls and symptomatic patients.
Proteomics said the trial delivered stunning accuracy in diagnosing cases across all stages of the debilitating disease.
The test is also being considered for use in women undergoing fertility treatments. Endometriosis is three times more common among IVF patients, where early intervention can be crucial. With fertility treatments on the rise globally, the commercial implications of PromarkerEndo could be significant.
Proteomics International has an expanding arsenal of precision diagnostics, all powered by its cutting-edge Promarker platform. The standard protein blood test is also behind the companyโs PromarkerD test for diabetic kidney disease and PromarkerEso for oesophageal cancer.
The commercial roll-out of PromarkerEndo is now squarely in sight, with Proteomics targeting an Australian launch in the third quarter of this year.
With a Japanese patent encouragingly under its belt, Proteomics will be eagerly anticipating approval applications it has pending in Australia, Canada, China, Europe, India, Singapore, Korea and the United States.
Those approvals could quickly turn from a trickle to a flood that unleashes the technology in some of the worldโs most advanced healthcare jurisdictions.
Is your ASX-listed company doing something interesting? Contact: mattbirney@bullsnbears.com.au
About The Author
